-
Durvalumab: Advancing Immunotherapy in Cancer Treatment(Post)
Quick Facts About DurvalumabWhat is Durvalumab?Durvalumab (Imfinzi) is a PD-L1 checkpoint inhibitor used in immunotherapy to treat various cancers, including non-small cell lung cancer (
DNA Assembly Cloning(Page) Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity
Exosomes: Tiny Messengers Revolutionizing Cancer Diagnosis and Therapy(Post)In the intricate world of cancer biology, a silent conversation is constantly unfolding between tumor cells and their environment. For decades, we viewed this dialogue as a one-way street, with cancer
Immunopeptidomics: Mapping the Hidden Landscape of the Cancer Immunome(Post)Imagine a high-stakes game of hide-and-seek where the seeker is your immune system and the hider is a master of disguise: cancer. For decades, we believed the 'wanted' posters for tumor cells were li
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Red Blood Cell Peroxidase Interference in Competitive ELISA(Post)QUICK ANSWER A researcher ran a competitive 2,3-bisphosphoglycerate (2,3-BPG) ELISA on red blood cell (RBC) lysate. The standard curve was textbook, yet every lysate sample read at the
Clinical Chemistry Assays(Page) T-Cell Co-Stimulation & Agonist Checkpoint Pathway(Page) One Ligand, Two Receptors, Opposite Jobs: TNFR1 vs TNFR2(Post)Blocking TNF cures rheumatoid arthritis in some patients and triggers demyelination in others. That is not a dosing problem, and it is not a patient-selection problem. It is the direct consequence of
Tiragolumab: Unlocking New Horizons in Cancer Immunotherapy(Post)Quick Facts About TiragolumabWhat is Tiragolumab?Tiragolumab is an anti-TIGIT monoclonal antibody developed to enhance immune responses against cancer cells. It is currently under invest
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
In Vivo Cell Depletion: Antibody Targets, Fc Mechanisms and Dosing(Post)A depletion experiment is only as good as the depletion you can prove. Injecting a functional-grade antibody and assuming the population is gone is the most common failure mode in in vivo immunology.
B-Cell Depletion: Why Anti-CD20 Spares the Antibody(Post)You can remove almost every B cell from an animal and barely move its antibody titre. That is not a failed experiment — it is the expected result, and it follows from one fact: CD20 is switched off a
Valider en labo vos anticorps pour western blot : testez 2–3 dilutions(Post)Valider en labo vos anticorps pour western blot : testez 2–3 dilutions Pour un Western blot fiable, choisissez un anticorps validé sur des lysats biologiques pertinents, plutôt qu’un anticorps choisi
Extracellular Vesicles in Neurodegenerative Disease: From Pathology to Therapeutic Potential(Post)In the intricate landscape of the brain, cells constantly communicate, sending and receiving messages that govern our thoughts, memories, and movements. For decades, scientists believed this communica
Ipilimumab and Nivolumab: Advancing Research on CTLA-4 in Cancer Therapy(Post)What You Need to Know About IpilimumabWhat is Ipilimumab?Ipilimumab is a monoclonal antibody that targets CTLA-4, a protein involved in downregulating the immune system, to boost the bod
Renal Cell Carcinoma: Understanding, Diagnosing, and Treating Kidney Cancer(Post)Renal Cell Carcinoma (RCC) is the most common form of kidney cancer, originating in the lining of the proximal renal tubules. RCC accounts for approximately 90% of all kidney cancers and
Typical Workflow of CRISPR-Cas9 Genome Editing(Post)Molecular Biology · ProtocolsTypical Workflow of CRISPR-Cas9 Genome EditingA CRISPR experiment is only as good as the steps around the cut. This guide walks the full workflow — designing and scoring a
Protocole ELISA contre les anticorps hétérophiles en clinique et labo(Post)Protocole ELISA contre les anticorps hétérophiles en clinique et labo Un résultat Elisa qui ne colle pas au tableau clinique évoque d’abord une interférence par anticorps hétérophiles, surtout sur un
Multiplex Assays(Page)GeniePlex Multiplex Assays | Bead-Based Multiplex Immunoassays | Assay Genie
Unveiling Prezalumab: Targeting the Role of Anti-CD47 in Cancer Immunotherapy(Post)What You Need to Know About PrezalumabWhat is Prezalumab?Prezalumab is a monoclonal antibody designed to target CD47, a protein often overexpressed in cancer cells to evade immune detect
TGF-Beta SMAD Signalling Pathway: Function, Readouts and Assays(Post)Almost all of the TGF-β in a tissue is already there, and almost none of it is active. That single fact reorganises how the pathway should be studied. Unlike most cytokines, TGF-β is deposited into t
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
Zolbetuximab: A Breakthrough in Targeting Claudin 18.2 for Cancer Treatment(Post)Quick Facts About ZolbetuximabWhat is Zolbetuximab?Zolbetuximab is a monoclonal antibody that targets Claudin 18.2, a protein overexpressed in gastric and pancreatic cancers, enhancing t
Bococizumab: Mechanism, Clinical Applications, and Biosimilars in Research(Post)Quick Facts About BococizumabWhat is Bococizumab?Bococizumab is a monoclonal antibody that targets PCSK9, a protein involved in cholesterol regulation.How Does Bococizumab Work?It inhibi
Vopratelimab: Unlocking the Potential of ICOS in Cancer Research(Post)What You Need to Know About VopratelimabWhat is Vopratelimab?Vopratelimab is an experimental monoclonal antibody that targets the Inducible T-cell CO-Stimulator (ICOS) protein, playing a
Cetuximab: A Revolutionary Drug in Cancer Therapy(Post)Quick Facts About CetuximabWhat is Cetuximab?Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), widely used in cancer therapy.How does Cetuximab wor
Murlentamab: Revolutionizing Cancer Research with Targeted Therapy(Post)Quick Facts About MurlentamabWhat is Murlentamab?Murlentamab is a novel monoclonal antibody designed to target CD47, a "don’t eat me" signal that helps cancer cells evade the immune syst
Indusatumab: Advancing Anti-CD47 Cancer Research with Biosimilar Innovations(Post)Quick Facts About IndusatumabWhat is Indusatumab?Indusatumab is an experimental antibody therapy targeting CD47, a protein that enables cancer cells to evade immune destruction.How does
T-Cell Co-Stimulation and Agonist Checkpoint Signalling Explained(Post)Signal 1 tells a T cell what it is looking at; signal 2 tells it whether to care. The same peptide–MHC engagement that launches a productive effector response can just as easily install an anergy pro
Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
Diabetes & Obesity Assays (Page) Passaging Hybridoma Cells: A Detailed Guide(Post)Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha
Vesencumab: Unlocking the Potential of Anti-CD47 in Cancer Research(Post)Quick Facts About VesencumabWhat is Vesencumab?Vesencumab is an experimental monoclonal antibody designed to target CD47, a key regulator of immune evasion in cancer cells.How Does Vesen
Fletikumab: Unlocking the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About FletikumabWhat is Fletikumab?Fletikumab is an investigational monoclonal antibody targeting CD47, a key immune checkpoint that enables cancer cells to evade immune dest
Basiliximab: Mechanism, Clinical Applications, and Research Advancements(Post)Quick Facts About BasiliximabWhat is Basiliximab?Basiliximab is a monoclonal antibody targeting the CD25 subunit of the IL-2 receptor, primarily used to prevent organ transplant rejectio
Tezepelumab: A Breakthrough in Severe Asthma Treatment and Research(Post)Quick Facts About TezepelumabWhat is Tezepelumab?Tezepelumab is a monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a key driver of airway inflammation in seve
Bevacizumab: Mechanism, Clinical Applications, and Biosimilar Insights(Post)Quick Facts About BevacizumabWhat is Bevacizumab?Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), inhibiting angiogenesis (the formation of ne
Icrucumab: Exploring the Role of Anti-Angiogenic Therapy in Cancer Research(Post)Quick Facts About IcrucumabWhat is Icrucumab?Icrucumab is a monoclonal antibody that targets vascular endothelial growth factor receptor-1 (VEGFR-1) to inhibit tumor angiogenesis.How Doe
Microglia and Neuroinflammation(Page) The Interferon Axis: Type I vs Type II Signalling Explained(Post)Both interferon families run through STAT1, and that single shared subunit is why they are so often conflated — and why conflating them is a mistake. Type I interferon assembles STAT1 into a three-pa
Proteins(Page)Recombinant Proteins: Cytokines, Growth Factors & More | Assay Genie
Multiplex ELISA Protocol(Page) Sirexatamab: Advancing CD47-Targeted Cancer Therapy and Research(Post)Quick Facts About SirexatamabWhat is Sirexatamab?Sirexatamab is an investigational monoclonal antibody designed to target CD47, a key immune checkpoint involved in cancer evasion.How Doe
Protein Glycosylation for Labs: Mechanisms, Workflows, and Reagent Tips(Post)Protein Glycosylation for Labs: Mechanisms, Workflows, and Reagent Tips Protein glycosylation is the enzymatic covalent attachment of sugar chains (glycans) to specific amino acid side chains, most co
Dilutions 1:10 et 1:100 : détecter l'effet crochet en ELISA en labo(Post)L’effet crochet est une chute paradoxale du signal ELISA lorsque la concentration d’analyte devient trop élevée, ce qui produit un résultat faussement bas, voire négatif. Il touche surtout les for
Secukinumab: A Comprehensive Guide to Its Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About SecukinumabWhat is SecukinumabSecukinumab is a monoclonal antibody that targets interleukin-17A (IL-17A), a key cytokine involved in inflammatory and autoimmune respons
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting(Post)What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Comment choisir une protéine cytokine pour votre étude(Post)Comment choisir une protéine cytokine pour votre étude Pour une mesure fonctionnelle in vitro, privilégiez une cytokine recombinante à activité biologique validée sur la lignée cible. Pour une admini
Personnalisation des tests multiplex : le guide technique pour bien commander(Post)Personnalisation des tests multiplex : le guide technique pour bien commander Si votre étude nécessite plusieurs analytes sur peu de volume, un panel multiplex personnalisé est souvent la meilleure o
Codrituzumab: Unveiling Its Role in Cancer Research and Treatment(Post)What You Need to Know About CodrituzumabWhat is Codrituzumab?Codrituzumab is an investigational monoclonal antibody targeting CD47, an immune checkpoint that regulates immune responses i
Custom ELISA Kits(Page)Custom ELISA Kit Development Service | Assay Genie
4 étapes pour des comptes rendus ELISA défendables en laboratoire(Post)Un compte rendu ELISA exploitable réunit l’objectif de l’essai, la référence et le lot du kit, la méthode suivie, les densités optiques brutes, le modèle d’ajustement retenu (4PL ou 5PL) et les fa
Six étapes pour un protocole ELISA sandwich reproductible en laboratoire(Post)Le protocole ELISA sandwich standard suit six étapes: revêtement du puits avec l’anticorps de capture, blocage, incubation des standards et échantillons, ajout de l’anticorps de détection, puis du
Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
TLR Innate Sensing Pathway: Receptors, MyD88/TRIF and Assays(Post)Toll-like receptors are the reason a milligram of endotoxin can kill a mouse. They are the fastest, least discriminating layer of immunity: germline-encoded sensors that read conserved microbial chem
ELISA Troubleshooting: Why You Can't Skip the Full Standard Curve(Post)Quick answer A researcher measuring dopamine in mouse brain tissue got no detectable signal and, with many samples to run, asked whether the full standard curve could be skipped to sav
Une courbe par plaque pour la courbe standard ELISA au laboratoire(Post)Une courbe par plaque pour la courbe standard ELISA au laboratoire Une courbe standard ELISA convertit les densités optiques mesurées en concentrations exploitables, à partir d’une série d’étalons de